50.60
-1.34(-2.58%)
Currency In USD
| Previous Close | 51.94 |
| Open | 52.05 |
| Day High | 52.52 |
| Day Low | 49.82 |
| 52-Week High | 63.06 |
| 52-Week Low | 7.58 |
| Volume | 977,807 |
| Average Volume | 1.37M |
| Market Cap | 2.15B |
| PE | -14.58 |
| EPS | -3.47 |
| Moving Average 50 Days | 45.96 |
| Moving Average 200 Days | 20.09 |
| Change | -1.34 |
If you invested $1000 in Celcuity Inc. (CELC) since IPO date, it would be worth $3,540.94 as of September 28, 2025 at a share price of $50.6. Whereas If you bought $1000 worth of Celcuity Inc. (CELC) shares 5 years ago, it would be worth $8,433.33 as of September 28, 2025 at a share price of $50.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress
GlobeNewswire Inc.
Sep 22, 2025 1:15 PM GMT
MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from
Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance
GlobeNewswire Inc.
Sep 09, 2025 8:01 PM GMT
MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (“Celcuity”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into an amendment to its existing senior
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
GlobeNewswire Inc.
Aug 27, 2025 8:05 PM GMT
MINNEAPOLIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration (“FDA”) agreed to acc